Collegium appoints Neil F. McFarlane to board; expands to nine directors

COLLEGIUM PHARMACEUTICAL, INC

Board expanded from 8 to 9 members; McFarlane appointed effective April 6, 2022.
Appointed director Neil F. McFarlane, 49, initial term until May 19, 2022 annual meeting.
Annual cash retainer of $50k prorated; RSUs with grant date value of $337,500 vesting one year from grant.
No family relationships or reportable related party transactions with existing directors/officers.
No arrangement with any other person for selection as director.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Neil F. McFarlane

director

COLL · COLLEGIUM PHARMACEUTICAL, INC

Effective: 2022-04-06
Filed: April 6, 2022, 7:59 PM ET

On April 6, 2022, the Board of Directors (the “Board”) of Collegium Pharmaceutical, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from eight to nine members and appointed Mr. Neil F. McFarlane, 49, as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Neil F. McFarlane was appointed as director at COLLEGIUM PHARMACEUTICAL, INC.

Action: appointed
Role: director

Exact text from the filing

On April 6, 2022, the Board of Directors (the “Board”) of Collegium Pharmaceutical, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from eight to nine members and appointed Mr. Neil F. McFarlane, 49, as a director of the Company.

View on SEC.gov

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001104659-22-043015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.